Ascendis Pharma to raise capital with convertible notes

Biotech firm Ascendis Pharma intends to offer convertible notes for a sum of USD 500m.

Photo: Kevin Grønnemann / MedWatch

Danish biotech firm Ascendis Pharma, which is listed in the US, wants to raise USD 500m by offering convertible notes, the company reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs